Evaluation of topical tranexamic acid effectiveness in the treatment of melasma
Phase 3
- Conditions
- Melasma.ChloasmaL81.1
- Registration Number
- IRCT20181208041882N9
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Women with melasma from 18 to 60 years
MMASI score greater than 8.5
Do not use oral contraceptives
The patient has not received medication to treat melasma in the last three months
Exclusion Criteria
Drug allergy
Breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of of melasma improvement. Timepoint: Weeks 0, 4, 8. Method of measurement: MASI ( Melasma Area Severity Index) Score.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie topical tranexamic acid's efficacy in melasma (L81.1) treatment?
How does topical tranexamic acid compare to oral administration in melasma clinical outcomes?
Which biomarkers correlate with response to tranexamic acid in melasma patients?
What adverse events are associated with topical tranexamic acid for melasma treatment?
Are there combination therapies with tranexamic acid that improve melasma management compared to monotherapy?